Eli Lilly and Company (NYSE:LLY) is Fi3 FINANCIAL ADVISORS LLC’s 5th Largest Position

Fi3 FINANCIAL ADVISORS LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 0.2% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 14,917 shares of the company’s stock after buying an additional 33 shares during the period. Eli Lilly and Company accounts for approximately 4.3% of Fi3 FINANCIAL ADVISORS LLC’s holdings, making the stock its 5th biggest position. Fi3 FINANCIAL ADVISORS LLC’s holdings in Eli Lilly and Company were worth $11,516,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Virtu Financial LLC boosted its holdings in shares of Eli Lilly and Company by 11.6% during the 4th quarter. Virtu Financial LLC now owns 7,288 shares of the company’s stock valued at $5,626,000 after purchasing an additional 757 shares during the last quarter. Quantbot Technologies LP boosted its holdings in shares of Eli Lilly and Company by 52.8% during the 4th quarter. Quantbot Technologies LP now owns 5,741 shares of the company’s stock valued at $4,432,000 after purchasing an additional 1,984 shares during the last quarter. Sciencast Management LP bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $832,000. ZEGA Investments LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $1,349,000. Finally, Millstone Evans Group LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $840,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.4 %

Shares of NYSE LLY opened at $839.44 on Friday. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. The stock has a market cap of $795.93 billion, a PE ratio of 71.69, a P/E/G ratio of 1.40 and a beta of 0.34. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The company has a 50-day moving average of $835.99 and a 200 day moving average of $839.87.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company declared that its board has authorized a stock repurchase plan on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to purchase up to 2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

Several research analysts have commented on the stock. Truist Financial increased their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a report on Friday, January 17th. Morgan Stanley set a $1,146.00 price target on shares of Eli Lilly and Company in a report on Thursday, March 6th. Finally, Citigroup lowered their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,009.72.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.